Media coverage about Merrimack Pharmaceuticals (NASDAQ:MACK) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 49.0766831377025 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Merrimack Pharmaceuticals (MACK) traded up $0.08 during trading hours on Friday, reaching $10.82. The company had a trading volume of 93,542 shares, compared to its average volume of 140,960. The stock has a market capitalization of $145.34, a price-to-earnings ratio of -1.48 and a beta of 1.73. Merrimack Pharmaceuticals has a 52-week low of $9.68 and a 52-week high of $39.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.35 and a current ratio of 3.35.
TRADEMARK VIOLATION WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3204686/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-merrimack-pharmaceuticals-mack-stock-price.html.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.